PT  - JOURNAL ARTICLE
AU  - Leiye Yu
AU  - Licong He
AU  - Bing Gan
AU  - Rujuan Ti
AU  - Qingjie Xiao
AU  - Hongli Hu
AU  - Lizhe Zhu
AU  - Sheng Wang
AU  - Ruobing Ren
TI  - Structural Insights into Sphingosine-1-phosphate Receptor Activation
AID  - 10.1101/2022.01.15.475352
DP  - 2022 Jan 01
TA  - bioRxiv
PG  - 2022.01.15.475352
4099  - http://biorxiv.org/content/early/2022/01/16/2022.01.15.475352.short
4100  - http://biorxiv.org/content/early/2022/01/16/2022.01.15.475352.full
AB  - As a critical sphingolipid metabolite, sphingosine-1-phosphate (S1P) plays an essential role in immune and vascular systems. There are five S1P receptors, designated as S1PR1-5, encoded in the human genome, and their activities are governed by endogenous S1P, lipid-like S1P mimics, or non-lipid-like therapeutic molecules. Among S1PRs, S1PR1 stands out due to its non-redundant functions, such as the egress of T and B cells from the thymus and secondary lymphoid tissues, making it a potential therapeutic target. However, the structural basis of S1PR1 activation and regulation by various agonists remains unclear. Here we reported four atomic resolution cryo-EM structures of Gi-coupled human S1PR1 complexes: bound to endogenous agonist d18:1 S1P, benchmark lipid-like S1P mimic phosphorylated Fingolimod ((S)-FTY720-P), or non-lipid-like therapeutic molecule CBP-307 in two binding modes. Our results revealed the similarities and differences of activation of S1PR1 through distinct ligands binding to the amphiphilic orthosteric pocket. We also proposed a two-step “shallow to deep” transition process of CBP-307 for S1PR1 activation. Both binding modes of CBP-307 could activate S1PR1, but from shallow to deep transition may trigger the rotation of the N-terminal helix of Gαi and further stabilize the complex by increasing the Gαi interaction with the cell membrane. We combine with extensive biochemical analysis and molecular dynamic simulations to suggest key steps of S1P binding and receptor activation. The above results decipher the common feature of the S1PR1 agonist recognition and activation mechanism and will firmly promote the development of therapeutics targeting S1P receptors.Competing Interest StatementThe authors have declared no competing interest.